Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immuron Ltd.
The Quality Lowdown: Wishing Wished-For FDA Re-Inspections Had Gone Better?
As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.
Lupin’s Corporate Quality Oversight Questioned In FDA Warning Letter
Two-month inspection during pandemic highlighted cross-contamination risks and process validation shortfalls at New Jersey plant.
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Common Treatment May Be Removed In Alcoholic Hepatitis Trials
Given effect corticosteroids have on patients, US FDA asks whether they can be excluded from use in alcoholic hepatitis clinical trials.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.